Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Good day and thank you for standing by. Welcome to the Akebia's Third Quarter 2024 Fi ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.06 per share when it actually produced a loss of $0.04, delivering a surprise of 33.33%.Over the last four quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share AKBA The Nasdaq Capital Market Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECT ...

Exhibit 99.1 Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights • Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 • Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo • Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code • Akebia to Host Conference Call at 8:00 a.m. ET on Novembe ...

Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code Akebia to Host Conference Call at 8:00 a.m. ET on November 7CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical com ...

Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. ESTCAMBRIDGE, Mass., Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, prior to the open of financial markets.Akebia will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please registe ...

Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.S. dialysis centers CAMBRIDGE, Mass., Oct. 22, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has signed a multi-year commercial contract with one of the nation's leading providers of kidney care services, expanding access to Vafseo® (vadadustat) for ...

U.S. Renal Care is a leading provider of in-center and home dialysis in the United StatesCAMBRIDGE, Mass., Oct. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's fastest-growing dialysis provider, today announced entry into a multi-year commercial supply contract encompassing all USRC dialysis centers. The contract enables USRC attending physicians ...

Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of careTrial aims to build a body of real-world evidence to understand the potential benefits of treating patients with VafseoCAMBRIDGE, Mass., Sept. 5, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's largest privately held and fastes ...

Akebia Therapeutics (AKBA) has seen its share price rise after it gained FDA approval for Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in late March this year.The approval of Vafseo tablets gave this Zacks Rank #2 (Buy) company its second FDA-approved product after Auryxia (ferric citrate), which is indicated for the control of serum phosphorus levels in adult patients with CKD on dialysis. The oral method of the use of Vafseo tablets makes it an easier-to-use ...